264 related articles for article (PubMed ID: 23592446)
1. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
2. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
4. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
To KKW; Wu WKK; Loong HHF
Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
7. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
14. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
15. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
16. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
[TBL] [Abstract][Full Text] [Related]
17. LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Wu Y; Yu DD; Hu Y; Cao HX; Yu SR; Liu SW; Feng JF
Biochem Biophys Res Commun; 2015 Nov; 467(4):900-5. PubMed ID: 26471306
[TBL] [Abstract][Full Text] [Related]
18. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
19. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Sano T; Takeuchi S; Nakagawa T; Ishikawa D; Nanjo S; Yamada T; Nakamura T; Matsumoto K; Yano S
Int J Cancer; 2013 Jul; 133(2):505-13. PubMed ID: 23319394
[TBL] [Abstract][Full Text] [Related]
20. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]